edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: InMed Pharmaceuticals
Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
InMed Pharmaceuticals — 14 videos in collection
In this interview , Eric Adams, chief executive officer of InMed Pharmaceuticals, provides an overview of InMed’s differentiated biosynthesis platform and its therapeutic pipeline of cannabinoids.
InMed Pharmaceuticals (TSX: IN) is a Canada-based biopharmaceutical company focused on manufacturing and developing cannabinoids. Its biosynthesis platform has the potential to produce cannabinoids at a lower cost and with improved purity compared to currently used methods. The company is also developing a proprietary pipeline, including INM-755 for epidermolysis bullosa, a serious, debilitating orphan indication.
Get access to the very latest content matched to your personal investment style.